Richard leads strategic planning and operations for the Global Medical and Scientific Affairs group at Onyx Pharmaceuticals. In his role, he ensures that the department is prepared for and executing on appropriate strategies to bring important oncology therapies to patients with certain blood cancers. Richard has over 15 years of experience in life sciences, spanning early drug discovery to commercialization and market optimization. He has held various roles at large biotech and smaller companies alike, including Genentech, Zephyr Health, and Campbell Alliance, which have enabled him to work on products in a variety of disease areas including oncology, cardiovascular disease, immunology, ophthalmology, and infectious disease.
Richard earned his PhD and BS degrees at the University of California, Riverside, in the areas of Toxicology and Biochemistry, respectively. He also holds an MBA from the University of Southern California.